- Home
- ATLC vs GYRE Comparison
ATLC vs GYRE Comparison
Compare ATLC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- GYRE
- Stock Information
- Founded
- ATLC 1996
- GYRE 2002
- Country
- ATLC United States
- GYRE United States
- Employees
- ATLC N/A
- GYRE N/A
- Industry
- ATLC Finance: Consumer Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ATLC Finance
- GYRE Health Care
- Exchange
- ATLC Nasdaq
- GYRE Nasdaq
- Market Cap
- ATLC 816.9M
- GYRE 755.7M
- IPO Year
- ATLC 1999
- GYRE N/A
- Fundamental
- Price
- ATLC $52.03
- GYRE $8.19
- Analyst Decision
- ATLC Buy
- GYRE Strong Buy
- Analyst Count
- ATLC 7
- GYRE 2
- Target Price
- ATLC $78.71
- GYRE $17.00
- AVG Volume (30 Days)
- ATLC 68.7K
- GYRE 60.0K
- Earning Date
- ATLC 11-10-2025
- GYRE 11-07-2025
- Dividend Yield
- ATLC N/A
- GYRE N/A
- EPS Growth
- ATLC 26.57
- GYRE N/A
- EPS
- ATLC 5.63
- GYRE 0.04
- Revenue
- ATLC $498,496,000.00
- GYRE $107,265,000.00
- Revenue This Year
- ATLC $367.57
- GYRE $15.25
- Revenue Next Year
- ATLC $35.94
- GYRE $33.14
- P/E Ratio
- ATLC $9.19
- GYRE $211.54
- Revenue Growth
- ATLC 33.26
- GYRE 2.13
- 52 Week Low
- ATLC $41.37
- GYRE $6.11
- 52 Week High
- ATLC $78.91
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ATLC 40.01
- GYRE 59.01
- Support Level
- ATLC $48.74
- GYRE $7.12
- Resistance Level
- ATLC $58.59
- GYRE $7.42
- Average True Range (ATR)
- ATLC 2.74
- GYRE 0.34
- MACD
- ATLC -0.31
- GYRE 0.04
- Stochastic Oscillator
- ATLC 25.75
- GYRE 94.82
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.